

Debora Basile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7878399/publications.pdf>

Version: 2024-02-01

46
papers

1,074
citations

471061

17
h-index

433756

31
g-index

46
all docs

46
docs citations

46
times ranked

2190
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021, 40, 286-294.	2.3	17
2	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	1.5	11
3	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021, 143, 147-157.	1.3	32
4	Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 602596.	1.3	3
5	The Clinical Value of Nutritional Care before and during Active Cancer Treatment. <i>Nutrients</i> , 2021, 13, 1196.	1.7	34
6	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	0.7	4
7	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 943-952.	1.5	23
8	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021, 57, 104-112.	0.9	14
9	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1221-1232.	1.3	2
10	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	1.7	5
11	First-line chemotherapy with raltitrexid in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	3
12	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1185, 122985.	1.2	16
13	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 451-462.	3.0	2
14	Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550185.	1.3	13
15	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	1.1	1
16	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	1.9	21
17	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1268-1273.	0.5	6
18	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020, 15, e0228822.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020, 10, 7010.	1.6	18
20	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102028.	3.4	9
21	Title is missing!., 2020, 15, e0228822.		0
22	Title is missing!., 2020, 15, e0228822.		0
23	Title is missing!., 2020, 15, e0228822.		0
24	Title is missing!., 2020, 15, e0228822.		0
25	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. <i>Cancers</i> , 2019, 11, 857.	1.7	77
26	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. <i>Cancers</i> , 2019, 11, 880.	1.7	11
27	The <sc>IMPACT</sc> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	2.9	61
28	Sarcopenia: looking to muscle mass to better manage pancreatic cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 279-285.	0.5	23
29	Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019, 29, 510-515.	0.6	12
30	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	3.4	88
31	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , 2019, 72, 7-14.	3.4	25
32	Prognostic evaluation in palliative care: final results from a prospective cohort study. <i>Supportive Care in Cancer</i> , 2019, 27, 2095-2102.	1.0	20
33	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 577-577.	0.8	0
34	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 203-225.	0.8	1
35	Atezolizumab for the treatment of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 595-603.	1.4	17
36	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 205-213.	1.1	8
38	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	0.5	29
39	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. <i>International Journal of Molecular Sciences</i> , 2018, 19, 47.	1.8	17
40	Sarcopenia in gastric cancer: when the loss costs too much. <i>Gastric Cancer</i> , 2017, 20, 563-572.	2.7	47
41	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	1.4	85
42	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	1.3	33
43	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017, 61, 15-22.	3.4	43
44	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	1.6	165
45	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 194.	0.8	46
46	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. <i>Translational Cancer Research</i> , 2016, 5, S765-S771.	0.4	2